D

Dr. Reddy's Laboratories Limited (RDY)

NYQ – Real vaqt narxi. Valyuta: USD

12.46

-0.68 (-5.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

D

Dr. Reddy's Laboratories Limited (RDY)

NYQ – Real vaqt narxi. Valyuta: USD

12.46

-0.68 (-5.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript

12.05.2026

Indian drugmaker Dr Reddy's posts quarterly profit slump

Indian drugmaker Dr Reddy's reported an 86% ‌slump in quarterly profit on Tuesday, hurt by pricing pressure and increasing competition ⁠in its key U.S. market.

29.04.2026

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the best option for those looking for undervalued stocks?

29.04.2026

Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic

The country is the first in the G7 forum to approve a generic version of the massively popular GLP-1 diabetes treatment.

29.04.2026

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection.

04.03.2026

3 Generic Drug Stocks to Watch Despite Industry Headwinds

Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.

20.02.2026

Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy's announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.

Videolar

No Data

There is no data to display

Press-relizlar

29.04.2026

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection.

20.02.2026

Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy's announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.

14.01.2026

Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Antihistamineeyedrop--Dr. Reddy's launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Strength Pataday® Once Daily Relief.

$Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies$

02.12.2025

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.

Search stocks

Dr. Reddy's Laboratories Limited (RDY)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Dr. Reddy's Laboratories Limited (RDY)

Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript

Indian drugmaker Dr Reddy's posts quarterly profit slump

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

3 Generic Drug Stocks to Watch Despite Industry Headwinds

Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Videolar

No Data

Press-relizlar

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies